<DOC>
	<DOCNO>NCT00817518</DOCNO>
	<brief_summary>This study determine maximum tolerate dose dose-limiting toxicity RO4987655 patient advance and/or metastatic solid tumor . In first part study , group patient sequentially enrol receive ascend oral dos RO4987655 daily 28 day . The start dose 1mg daily escalate subsequent group patient successful assessment safety tolerability previous dose . In Part 2 study , patient metastatic advance malignant melanoma , responsive tumor type , randomize receive either maximum tolerate dose optimal biological dose RO4987655 daily . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Dose-Escalating Study RO4987655 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>adult patient , &gt; =18 year age ; advanced and/or metastatic cancer amenable standard therapy ; solid tumor type ( Part 1 ) ; malignant melanoma responsive tumor type ( Part 2 ) ; measurable and/or evaluable disease ( Part 1 ) ; &gt; =1 measurable lesion ( Part 2 ) ; ECOG performance status 02. prior chemotherapy , radiotherapy immunotherapy within 28 day first receipt study drug ; prior corticosteroid anticancer therapy within 14 day first receipt study drug ; active CNS lesion ; acute chronic infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>